Company profile: Innovation Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies addressing unmet medical needs, developing Brilacidin, a small-molecule drug candidate with immunomodulatory, anti-inflammatory, and antimicrobial properties tested for COVID-19, oral mucositis, inflammatory bowel disease, serious skin infections, and fungal diseases; and BEAMED, an image-guided surgical laser platform under development for treating cancer and epilepsy.
Products and services
- BEAMED: Engineers an image-guided surgical laser platform under development for treating cancer and epilepsy, integrating imaging with laser control to guide operative targeting
- Brilacidin: Produces a drug candidate with immunomodulatory, anti-inflammatory, and antimicrobial properties, tested in COVID-19, oral mucositis, inflammatory bowel disease, serious skin infections, and fungal diseases
- Small Molecule Therapeutics R&D: Develops small molecule therapies in areas of unmet medical needs, creating candidate medicines to address those unmet medical needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Innovation Pharmaceuticals
Trevi Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for uremic pruritus and chronic cough, including Haduvio—an investigational oral nalbuphine ER therapy targeting the central and peripheral nervous systems for idiopathic pulmonary fibrosis (IPF)-related cough and refractory chronic cough (RCC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trevi Therapeutics company profile →
Imbria
HQ: United States
Website
- Description: Provider of clinical-stage cardiometabolic therapies centered on ninerafaxstat, an investigational cardiac mitotrope designed to enhance cellular energy metabolism by increasing energy per molecule of oxygen consumed. Conducts Phase 2 trials: IMPROVE-HCM (non-obstructive HCM), IMPROVE-ISCHEMIA (stable angina/chronic coronary syndrome), and IMPROVE-DiCE (type 2 diabetes with HFpEF).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imbria company profile →
The Medicines Company
HQ: United States
Website
- Description: Provider of innovative, cost-effective medicines to the worldwide hospital marketplace, focused on advancing treatment of critical care patients. Markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full The Medicines Company company profile →
Lin Bioscience
HQ: Taiwan
Website
- Description: Provider of innovative drug therapies addressing unmet medical needs, developing: LBS-008, an oral treatment for dry age-related macular degeneration and Stargardt disease; LBS-007, a CDC7 inhibitor for leukemia and solid tumors; LBS-002, an anti-tubulin therapy for brain tumors that crosses the blood-brain barrier; and LBS-009, an oral therapy for NAFLD and type 2 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lin Bioscience company profile →
Syntaxin
HQ: United Kingdom
Website
- Description: Provider of bacterial-based protein therapeutics for neurological, inflammatory and endocrine diseases, leveraging a proprietary technology platform to engineer bacterial proteins via domain substitution.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syntaxin company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Innovation Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Innovation Pharmaceuticals
2.2 - Growth funds investing in similar companies to Innovation Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Innovation Pharmaceuticals
4.2 - Public trading comparable groups for Innovation Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →